Dianthus Therapeutics Inc

At the Cantor Fitzgerald Healthcare Conference, Dianthus Therapeutics presented robust Phase II/III data for claseprubart in myasthenia gravis and CIDP that have roughly tenfold increased the market valuation over the past 12 months. The CIDP interim data showed a 75% response rate in the first 40 patients, leading to reduced recruitment targets and shorter study duration; a regulatory plan foresees an initial BLA for myasthenia gravis followed by a supplement for CIDP. Dianthus is also advancing two follow‑on programs (DNTH312, DNTH212) that could target additional indications, and expects multiple study data updates in the coming years. Management emphasizes lower development risk due to rapid execution but continues to see regulatory, operational and competitive risks. » More on de.investing.com

Dianthus highlighted progress with Claseprubart in myasthenia gravis, CIDP and MMN, and a strong liquidity position of $1.2 billion intended to fund operations through 2030. Key near‑term events are top‑line MMN results in December 2026, a CIDP recruitment update at the end of 2026, and expected Phase‑III results in MG in the second half of 2028. The company also plans further development with DNTH212 (Phase I) and the follow‑on DNTH312 (Phase‑I readiness expected at the end of 2027) to drive long‑term value. » More on de.investing.com